Calquence (acalabrutinib tablets) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has tried at least one systemic regimen [examples include Brukinsa (zanubrutinib capsules), Imbruvica (ibrutinib tablets, capsules, and oral solution), rituximab, bendamustine, cyclophosphamide, dexamethasone, bortezomib, Kyprolis (carfilzomib intravenous infusion), or Ninlaro (ixazomib capsule)]

Approval duration

1 year